K.C. Pharmaceuticals Recalls 3.1 Million Eye Drop Bottles Over Sterility Concerns
K.C. Pharmaceuticals has initiated a massive recall of over 3.1 million bottles of lubricating eye drops due to failures in proving product sterility. The recall, announced in March 2026, affects eight specific products sold under various brand names including Top Care, Walgreens, and CVS at major US retailers. This marks the second time since 2023 that the FDA has identified sterility issues with the company's manufacturing processes. While no infections have been reported as of early April 2026, experts warn that nonsterile eye drops can cause severe eye infections because the immune system struggles to fight microbes in the eyeball. Consumers are urged to check lot numbers and expiration dates on the FDA website. If their products match the recalled items, they should stop use immediately and seek refunds. Symptoms such as redness, discharge, or vision changes require immediate medical attention. The incident highlights ongoing challenges in pharmaceutical manufacturing oversight and FDA inspection capabilities regarding over-the-counter health products.
Wire timeline
K.C. Pharmaceuticals Recalls 3.1 Million Eye Drop Bottles Over Sterility Concerns
K.C. Pharmaceuticals has initiated a massive recall of over 3.1 million bottles of lubricating eye drops due to failures in proving product sterility. The recall, announced in March 2026, affects eight specific products sold under various brand names including Top Care, Walgreens, and CVS at major US retailers. This marks the second time since 2023 that the FDA has identified sterility issues with the company's manufacturing processes. While no infections have been reported as of early April 2026, experts warn that nonsterile eye drops can cause severe eye infections because the immune system struggles to fight microbes in the eyeball. Consumers are urged to check lot numbers and expiration dates on the FDA website. If their products match the recalled items, they should stop use immediately and seek refunds. Symptoms such as redness, discharge, or vision changes require immediate medical attention. The incident highlights ongoing challenges in pharmaceutical manufacturing oversight and FDA inspection capabilities regarding over-the-counter health products.
cnn